论文部分内容阅读
HoechstMarionRoussel公司的静注用多拉司琼（dolasetron，商品名Anzeme）获美国FDA许可用于治疗术后恶心和呕吐（PONV）。这是继本品50和100mg片剂，一日1次口服给药预防PONV新近获得批准之后获得的。本品将是第一个用于治疗术后恶心的注射用5－羟色胺拮抗剂。一项有703例病人
Hoechst Marion Roussel’s intravenous infusion of dolasetron (Anzeme) was approved by the U.S. FDA for the treatment of postoperative nausea and vomiting (PONV). This is the product of 50 and 100mg tablets, oral administration once a day to prevent PONV recently obtained after approval. This product will be the first 5-HT antagonist for postoperative nausea. A total of 703 patients